Hospira Acquires Orchid's API Manufacturing and R&D Facilities
PTSM: Pharmaceutical Technology Sourcing and Management
Hospira acquires assets from Orchid Chemicals & Pharmaceuticals for $218 million.
Hospira reported it has completed the acquisition of an API manufacturing facility and an associated R&D facility from Orchid Chemicals & Pharmaceuticals, an Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.
The acquisition enables Hospira to vertically integrate into the beta-lactam antibiotic APIs (penems and penicillins) and is also expected to improve Hospira's cost position in this therapeutic space. In addition, backward integration into these beta-lactam APIs will improve the company's security of supply.
The API manufacturing facility, located in Aurangabad, India has capabilities for manufacturing sterile APIs and employs approximately 665 employees including chemists, engineers, and technicians. The associated R&D facility is based in Chennai, India, and will be directed primarily to beta-lactam and other API developments with approximately 110 scientific personnel.
Post deal, Orchid retains its cephalosporin API business and facilities and certain non-antibiotic, non-sterile businesses, and facilities it owns. Orchid will continue to supply Hospira with cephalosporin APIs.
Source: Hospira
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
